Category Archives: Business and Investments

Latest From Business and Investments

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

See What’s New at the 2015 BIO Investor Forum

hyde pier

The 2015 BIO Investor Forum is just two weeks away, and it’s gearing up to be the most productive Forum yet. The event will take place October 20-21, 2015 at the Parc 55 Hotel in San Francisco, California, and will feature several new programs and activities for attendees. Register now to join your colleagues for an exciting two days of networking, company presentations, BIO One-on-OneTM partnering meetings, and exciting expert-led panels. Here’s what to expect Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Politicking Biopharma Delays Cures

US Capitol Building

Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of ARCH Venture Partners, which addresses the challenges our industry is currently facing amid the continued need for biomedical innovation. Read it here.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

Warning: Don’t Let Bio-Euphoria Distract You from Being Disciplined

DNA

This piece by Allan L. Shaw was originally published in Life Science Leader. We currently in a period I call “bio-euphoria,” in which the biopharmaceutical industry is experiencing growth in almost every area from market performance to patient-focused legislation. In parallel to this positive momentum, there has also been a notable shift in management and operational strategy by Big Pharma companies in an attempt to keep evolving with the market. These companies are taking creative Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,